Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$307.80 USD

307.80
3,427,831

+6.66 (2.21%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $307.00 -0.80 (-0.26%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 29% (175 out of 247)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

The Zacks Analyst Blog Highlights Moodys, Stryker and CBRE

by Zacks Equity Research

Zacks highlights three wide-moat leaders Moody's, Stryker, and CBRE poised to deliver durable returns through strong fundamentals, innovation, and strategic expansion.

Nalak Das headshot

Buy 3 Wide Moat Stocks to Enhance Your Portfolio Returns in Q4

by Nalak Das

MCO, SYK and CBRE stand out as wide moat stocks with strong growth forecasts and strategic expansions to boost portfolio resilience.

Indrajit Bandyopadhyay headshot

Will ISRG's dV5 Lend Momentum to Top Line During Q3 Earnings?

by Indrajit Bandyopadhyay

Intuitive Surgical's new da Vinci 5 is driving strong hospital upgrades and premium pricing, setting up ISRG for potential top-line momentum in Q3.

Zacks Equity Research

Zacks.com featured highlights include Stryker, NVIDIA, ResMed and Ralph Lauren

by Zacks Equity Research

Zacks highlights four GARP (Growth at a Reasonable Price) stocks Stryker, NVIDIA, ResMed, and Ralph Lauren combining strong growth prospects with attractive valuations for maximum returns.

Vasundhara Sawalka headshot

4 GARP Stocks That Investors Can Scoop Up for Maximum Returns

by Vasundhara Sawalka

Try the GARP strategy when seeking a profitable portfolio of stocks offering optimum value and growth investing. SYK, NVDA, RMD and RL hold promise.

Kinjel Shah headshot

J&J Bets on MedTech Growth With Orthopaedics Unit Spin-Off Plan

by Kinjel Shah

J&J's surprise plan to spin off its Orthopaedics unit as DePuy Synthes is aimed at sharpening MedTech focus and boosting growth margins.

Indrajit Bandyopadhyay headshot

Can ISRG Continue Its Strong Growth Amid Tariff & Rare Earth Woes?

by Indrajit Bandyopadhyay

ISRG's growth momentum faces pressure as tariffs and China's rare earth export curbs threaten margins and supply stability.

Kinjel Shah headshot

Is J&J's MedTech Segment Set for Another Quarter of Growth?

by Kinjel Shah

J&J's MedTech sales are gaining traction in Cardiovascular, Surgery, and Vision, even as China???s VBP program continues to weigh on growth.

Zacks Equity Research

SNN or SYK: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

SNN vs. SYK: Which Stock Is the Better Value Option?

Zacks Equity Research

ZBH Receives PMDA Approval in Japan for iTaperloc Complete and iG7

by Zacks Equity Research

Zimmer Biomet wins early PMDA approval in Japan for its iTaperloc Complete and iG7 Hip System with Iodine Technology.